Upgrade to SI Premium - Free Trial

Mizuho on Sarepta Therapeutics (SRPT): data de-risks siRNA platform, supports BIC potential

March 25, 2026 10:46 AM
Mizuho analyst Uy Ear reiterated an Outperform rating and $31.00 price target on Sarepta Therapeutics (NASDAQ: SRPT)The analyst commented, "This ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments

Next Articles